Figure 2

Proposed regulatory effects of miR-205 and miR-184 on SHIP2 levels in various epithelial contexts. (a) Epidermal keratinocytes. Decreasing miR-205 via antagomir-205 increases SHIP2 levels, resulting in the dampening of Akt signalling and an increase in apoptosis and cell death. (b) Corneal keratinocytes. Decreasing miR-184 via antagomir-184 'releases' miR-205 to reduce SHIP2 levels, augmenting the Akt pathway, with increased cell survival and angiogenesis as possible outcomes. Since miR-184 does not inhibit SHIP2, decreasing miR-205 via antagomir-205 disturbs the normal balance between SHIP2 and miR-184/205. (c) Squamous cell carcinoma (SCC). Ectopic expression of miR-184 or treatment with an antagomir to miR-205 represents potential therapeutic modalities for the treatment of SCCs by increasing SHIP2 levels, which might act as a tumour suppressor in these neoplasias. Reprinted from Yu et al. [110]